Treatment algorithm

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer

ACUTE

hospitalized active smokers

Back
1st line – 

brief or comprehensive intervention for smoking cessation

Hospital admissions present a window of opportunity to initiate cessation interventions in active smokers for several reasons: if admitted for a smoking-related illness, active smokers may have increased motivation to quit; as most hospitals are smoke-free, smokers have enforced abstinence from smoking; some hospitals have trained specialist clinicians to assist with smoking cessation; those eligible to receive pharmacotherapy can be instructed on its use and can experience it while being observed.

The initial approach to smoking cessation varies according to location of practice. Two commonly used models are:​ i) a brief intervention for smoking cessation, commonly based on an “Ask, Advise, Assist” structure, which encourages clinicians to ask patients about tobacco use, advise them to quit, and assist them by signposting them to specialist smoking cessation services offering pharmacotherapy and behavioral counseling; ii) a more comprehensive intervention for smoking cessation, which can be provided using the "5 A's" structure: 1) ask about tobacco use; 2) advise to quit through clear, personalized messages; 3) assess willingness to quit; 4) assist in quitting; and 5) arrange follow-up and support.[71]

Both brief and comprehensive smoking cessation models may be used within an inpatient hospital setting. Evidence directly comparing smoking cessation models is limited. It suggests that both brief and comprehensive models can be effective, but that effectiveness may vary depending on the individual and on the clinical setting.[1]​ Clinicians may choose to prioritize for comprehensive interventions those with greater nicotine dependence, or previous unsuccessful quit attempts.

When patients receive behavioral counseling in the hospital, high‐certainty evidence indicates that providing both behavioral counseling and pharmacotherapy after discharge increases quit rates compared with no post‐discharge intervention.[169]

One effective program for inpatient smoking cessation is the Ottawa Model for Smoking Cessation, which improves long-term quit rates by 11%, and involves identification of smoking status for all admitted patients, brief advice, personalized bedside smoking cessation, behavioral counseling, timely pharmacotherapy, and follow-up after discharge.[172] University of Ottawa Heart Institute: Ottawa model for smoking cessation​ Opens in new window

Back
Plus – 

behavioral counseling

Treatment recommended for ALL patients in selected patient group

There is high-certainty evidence to suggest that behavioral counseling by a trained cessation specialist initiated during the admission to the hospital and continued for more than 1 month after discharge is effective in increasing quit rates regardless of the admitting diagnosis.[169] [ Cochrane Clinical Answers logo ] ​ Behavioral counseling provided only in the hospital, without post-discharge support, may have a modest impact on quit rates, but the evidence is less certain.[169] Therefore, active smokers should be connected with outpatient behavioral counseling resources at discharge, where possible.[170]

Cochrane reviews determined that group-based interventions appear to be more promising than individual-based interventions.​[113][161]

Back
Consider – 

nicotine replacement therapy (NRT) and/or varenicline

Treatment recommended for SOME patients in selected patient group

Evidence supports an improvement in quit rates when NRT is added to behavioral counseling in patients admitted to the hospital.[169] NRT may also help relieve withdrawal symptoms during the enforced abstinence from smoking. One retrospective review of observational studies demonstrated that perioperative NRT is not associated with adverse outcomes after surgery.[171]

NRT has been considered safe in hospitalized patients including in patients admitted for acute coronary syndrome, and is recommended for use by the American College of Cardiology.[89] We suggest individualizing therapy depending on patient variables.

In the US, nonpharmacologic options are considered first line for pregnant or breastfeeding women, and adolescents.[2]​​[62][71]​​​ Consult a specialist for guidance on selection of treatment in pregnant/breastfeeding women and adolescents.

There is moderate-certainty evidence to suggest that starting varenicline in hospitalized patients helps more patients to quit smoking than placebo or no medication.[169] There is insufficient evidence on the effectiveness or safety of varenicline for smoking cessation in pregnancy.[158]

Most tobacco cessation monotherapies and combination therapies are more effective than placebo at helping participants to achieve sustained abstinence.[136] Combining drugs with different mechanisms of action may increase quit rates more than single agents.[76] One network meta-analysis showed a high probability that the combination of varenicline and NRT is more likely to achieve sustained abstinence than NRT or bupropion as monotherapies.[136] However, one randomized controlled trial showed no significant difference in abstinence among those treated with combined varenicline plus nicotine patch therapy versus varenicline monotherapy.[137] Combining varenicline with NRT agents has been associated with higher rates of adverse effects (e.g., nausea, headaches).[2]

The choice of nicotine delivery method is guided by patient preferences, prior experience, and availability. In most countries, the patch, gum, and lozenges are available without a prescription. The nasal spray generally requires a prescription. An inhaler and nicotine mouth spray may be available in some countries, but they are not currently available in the US.[76] Product literature should be consulted for further guidance on dosage of specific brands of NRT products.

Primary options

nicotine transdermal: 21 mg once daily for 6 weeks initially, followed by 14 mg once daily for 2 weeks, followed by 7 mg once daily for 2 weeks

More

or

nicotine transmucosal: 2-4 mg lozenge or gum every 1-2 hours for 6 weeks, then taper gradually over 6 weeks, maximum 5 lozenges/6 hours or 20 lozenges/day or 24 gum pieces/day

or

nicotine nasal: 0.5 mg (1 spray) in each nostril once or twice an hour initially, adjust dose according to response, maximum 10 sprays/hour or 80 sprays/day

-- AND / OR --

varenicline: 0.5 mg orally once daily for 3 days initially, followed by 0.5 mg twice daily for 4 days, followed by 1 mg twice daily for 12-24 weeks

ONGOING

active smokers ready to quit: adults (not pregnant/breastfeeding)

Back
1st line – 

brief or comprehensive intervention for smoking cessation

The initial approach to smoking cessation varies according to location of practice. Two commonly used models are:​ i) a brief intervention for smoking cessation, commonly based on an “Ask, Advise, Assist” structure, which encourages clinicians to ask patients about tobacco use, advise them to quit, and assist them by signposting them to specialist smoking cessation services offering pharmacotherapy and behavioral counseling; ii) a more comprehensive intervention for smoking cessation, which can be provided using the "5 A's" structure: 1) ask about tobacco use; 2) advise to quit through clear, personalized messages; 3) assess willingness to quit; 4) assist in quitting; and 5) arrange follow-up and support.[71]

Evidence directly comparing smoking cessation models is limited. It suggests that both brief and comprehensive models can be effective, but that effectiveness may vary depending on the individual and on the clinical setting.[1]​ Clinicians may choose to prioritize for comprehensive interventions those with greater nicotine dependence, or previous unsuccessful quit attempts.

Following the initial clinical contact, clinicians should offer a menu of cessation resources (medicines and behavioral counseling) to those who are ready to quit. Overall, the combination of behavioral counseling plus an evidence-based medication for smoking cessation has the best evidence for smoking cessation.[2][96] [ Cochrane Clinical Answers logo ] ​​ Some people may choose to attempt smoking cessation with behavioral counseling alone.

Back
Plus – 

behavioral counseling

Treatment recommended for ALL patients in selected patient group

Behavioral counseling has consistently shown benefit for smoking cessation, compared with receiving minimal support, or receiving pharmacotherapy alone.​[114][115]​​ Cochrane review evidence suggests that increasing the amount of behavioral counseling available increases the chance of success by about 10% to 20%.[98]​ Another Cochrane review determined that group-based interventions in adults appear to be more promising than self-help and other less intensive interventions. There was not enough evidence to evaluate whether groups are more effective than intensive individual behavioral counseling.[113] There is moderate-certainty evidence that the provision of adjunctive behavioral counseling by a health professional other than the physician (e.g.. nurse, smoking cessation specialist, smoking quitline) increases smoking cessation rates in primary care.[116]

Internet-based interventions are available that increase the likelihood of cessation and help patients avoid relapse.[117][118] [ Cochrane Clinical Answers logo ] ​​ Text messaging interventions have been shown to have a beneficial impact on 6-month cessation outcomes.[119][120] [ Cochrane Clinical Answers logo ] ​​ Financial-incentive programs have been shown to improve tobacco cessation rates in both low- and high-income groups.[121][122]​​[123]​​

Reward-based programs are more commonly accepted than deposit-based programs and have led to higher smoking cessation rates.[124]

Back
Consider – 

nicotine replacement therapy (NRT) and/or varenicline

Treatment recommended for SOME patients in selected patient group

Two types of medicines have amassed the greatest volume of data demonstrating safety and efficacy for smoking cessation: NRT with a combination of short-acting and long-acting NRT (patches, gum, lozenges, and nasal spray), and varenicline.​[125][126][127][128]​​​ Both are considered first-line treatments and produce significantly higher quit rates for 6 months or more than does placebo alone.[63][76]

NRTs attenuate withdrawal symptoms and can provide a coping strategy for the behavioral aspects of withdrawal, such as oral (gum, lozenge) and hand-to-mouth (inhaler) stimulation. There is strong evidence that adding a short-acting "on-demand" form of NRT (e.g., gum, lozenge) to a long-acting nicotine patch increases success rates, and so this strategy is preferred over monotherapy where possible.[53][63][125][127][129]​​​​​ Evidence from one Cochrane review suggests that lower-dose nicotine patches and gum may be less effective than higher-dose products.[53] 

The choice of nicotine delivery method is guided by patient preferences, prior experience, and availability. In most countries, the patch, gum, and lozenges are available without a prescription. The nasal spray generally requires a prescription. An inhaler and nicotine mouth spray may be available in some countries, but they are not currently available in the US.[76]​ Product literature should be consulted for further guidance on dose of specific brands of NRT products. NRT should be started at the same time as the planned quit date.

Varenicline attenuates withdrawal symptoms and blocks the reinforcing effects of nicotine. It has been shown to increase the chances of successful long-term smoking cessation by 2-3 times compared with placebo.[130]​ More people quit successfully with varenicline than with bupropion or with a single form of NRT. Varenicline may be as effective as or more effective than dual-form NRT.[130][131] [ Cochrane Clinical Answers logo ] ​​​ [ Cochrane Clinical Answers logo ] ​​​​ Guidance from the American Thoracic Society (ATS) and a statement from the American College of Cardiology both recommend varenicline over bupropion or NRT.[89][132]​​​​ Varenicline combined with behavioral counseling increases abstinence more than other pharmacotherapy with behavioral counseling combinations.[133]​ Early reports of possible links of varenicline to cardiovascular and psychiatric events have not been confirmed by current research.[90][131][134]​​​​ There is evidence from one Cochrane review that people taking varenicline may be at increased risk of adverse cardiac events, but at decreased risk of neuropsychiatric adverse events, although the evidence was equivocal and compatible with both benefit and harm.[130] Physicians should consider warning patients of the potential for these effects and advising them to seek medical help if the patient (or their family or caregiver) observes any mood or behavioral changes.[196] Varenicline is relatively slow-acting, and so should be started 1-2 weeks in advance of the quit date.[63]​ To prevent nausea, varenicline can be taken after meals with a full glass of water, dosage can be increased slowly, or dose can be reduced.

Most tobacco cessation monotherapies and combination therapies are more effective than placebo at helping participants to achieve sustained abstinence.[136]​ Combining drugs with different mechanisms of action may increase quit rates more than single agents.[76] One network meta-analysis showed a high probability that the combination of varenicline and NRT is more likely to achieve sustained abstinence than NRT or bupropion as monotherapies.[136] However, one randomized controlled trial showed no significant difference in abstinence among those treated with combined varenicline plus nicotine patch therapy versus varenicline monotherapy.[137]​ Combining varenicline with NRT agents has been associated with higher rates of adverse effects (e.g., nausea, headaches).[2]

In some locations, nicotine e-cigarettes may be considered in certain circumstances as an alternative to conventional NRT. Unlike conventional NRT, nicotine e-cigarettes are not licensed medicines, and their regulation and quality control varies across different countries and regions. Their use for smoking cessation is a topic of ongoing debate and research. There is a mounting body of evidence demonstrating that nicotine e-cigarettes are an effective method of nicotine delivery and can be used as NRT.[63][128][138]​​​​​​[139]​​[140] [ Cochrane Clinical Answers logo ] ​​​​​​​​ While they are generally considered to be less harmful than combustible cigarettes, their use as tobacco cessation aids remains controversial due to limited evidence on current devices, and uncertainty about possible health risks of long-term use.[140] Many countries (including the US) currently take a precautionary approach, and recommend against the use of e-cigarettes for smoking cessation.[1][71][72]​​​​ In the UK, recommendations on nicotine e-cigarette use for smoking cessation are more supportive.[63][197]​​​​​​​[198]

Primary options

nicotine transdermal: 21 mg once daily for 6 weeks initially, followed by 14 mg once daily for 2 weeks, followed by 7 mg once daily for 2 weeks

More

or

nicotine transmucosal: 2-4 mg lozenge or gum every 1-2 hours for 6 weeks, then taper gradually over 6 weeks, maximum 5 lozenges/6 hours or 20 lozenges/day or 24 gum pieces/day

or

nicotine nasal: 0.5 mg (1 spray) in each nostril once or twice an hour initially, adjust dose according to response, maximum 10 sprays/hour or 80 sprays/day

-- AND / OR --

varenicline: 0.5 mg orally once daily for 3 days initially, followed by 0.5 mg twice daily for 4 days, followed by 1 mg twice daily for 12-24 weeks

Back
2nd line – 

brief or comprehensive intervention for smoking cessation

The initial approach to smoking cessation varies according to location of practice. Two commonly used models are:​ i) a brief intervention for smoking cessation, commonly based on an “Ask, Advise, Assist” structure, which encourages clinicians to ask patients about tobacco use, advise them to quit, and assist them by signposting them to specialist smoking cessation services offering pharmacotherapy and behavioral counseling; ii) a more comprehensive intervention for smoking cessation, which can be provided using the "5 A's" structure: 1) ask about tobacco use; 2) advise to quit through clear, personalized messages; 3) assess willingness to quit; 4) assist in quitting; and 5) arrange follow-up and support.[71]

Evidence directly comparing smoking cessation models is limited. It suggests that both brief and comprehensive models can be effective, but that effectiveness may vary depending on the individual and on the clinical setting.[1]​ Clinicians may choose to prioritize for comprehensive interventions those with greater nicotine dependence, or previous unsuccessful quit attempts.

Following the initial clinical contact, clinicians should offer a menu of cessation resources (medicines and behavioral counseling) to those who are ready to quit. Overall, the combination of behavioral counseling plus an evidence-based medication for smoking cessation has the best evidence for smoking cessation.[2][96] [ Cochrane Clinical Answers logo ] ​ Some people may choose to attempt smoking cessation with behavioral counseling alone.

Back
Plus – 

behavioral counseling

Treatment recommended for ALL patients in selected patient group

Behavioral counseling has consistently shown benefit for smoking cessation, compared with receiving minimal support, or receiving pharmacotherapy alone.​[114][115]​​ Cochrane review evidence suggests that increasing the amount of behavioral counseling available increases the chance of success by about 10% to 20%.[98]​ Another Cochrane review determined that group-based interventions in adults appear to be more promising than self-help and other less intensive interventions. There was not enough evidence to evaluate whether groups are more effective than intensive individual behavioral counseling.[113] There is moderate-certainty evidence that the provision of adjunctive behavioral counseling by a health professional other than the physician (e.g.. nurse, smoking cessation specialist, smoking quitline) increases smoking cessation rates in primary care.[116]

Internet-based interventions are available that increase the likelihood of cessation and help patients avoid relapse.[117][118] [ Cochrane Clinical Answers logo ] ​​ Text messaging interventions have been shown to have a beneficial impact on 6-month cessation outcomes.[119][120] [ Cochrane Clinical Answers logo ] ​ Financial-incentive programs have been shown to improve tobacco cessation rates in both low- and high-income groups.[121][122]​​[123]​​​​​​

Reward-based programs are more commonly accepted than deposit-based programs and have led to higher smoking cessation rates.[124]

Back
Consider – 

bupropion or nortriptyline

Treatment recommended for SOME patients in selected patient group

Bupropion has received Food and Drug Administration (FDA) approval for smoking cessation, and is recommended in the UK by the National Institute for Clinical Excellence (NICE) as one option for smoking cessation, although NICE notes that it is less effective than combination nicotine replacement therapy (NRT) and varenicline.[63]​ Demonstrated to increase smoking cessation rates; it is as effective as single NRT, and has been shown to increase the chances of long-term abstinence by approximately 50% to 80% compared with placebo.​[125][126]​​​ It is less effective than varenicline.​[125][126]​​ Use of bupropion increases the risk of psychiatric adverse events, and is less well tolerated than placebo.[126] Significant contraindications include seizures, eating disorders, and use of monoamine oxidase inhibitors. People with active alcohol or substance use disorder may have a reduced threshold for seizures, increasing the risk of this complication from treatment with bupropion. Bupropion is relatively slow-acting, and so should be started 1-2 weeks in advance of the quit date.[63]

Nortriptyline has not received FDA approval for smoking cessation, and is not recommended by NICE in the UK.[63]​ Nortriptyline has demonstrated low-moderate efficacy for smoking cessation.[126][128]​ One Cochrane review found evidence that nortriptyline aided smoking cessation when compared with placebo, but also some evidence that it was inferior to bupropion; findings were sparse and inconsistent as to whether nortriptyline had a particular benefit for people with current or previous depression. Data on harms and tolerability were limited.[126] Considered a second-line therapy for smoking cessation due to higher rates of adverse events; these include arrhythmias and changes in contractility and blood flow. Treatment is started 12-28 days before quit date and continued for 12 weeks, then tapered gradually.

Either bupropion or nortriptyline may be considered In people with current depression, given that they are both antidepressants, although data to support this approach are limited, and as a general guide, first-line treatments for smoking cessation should be considered preferentially.[126] 

Evidence to support the use of combination therapy with bupropion and NRT is not strong and its use is somewhat controversial. The US Public Health Service guidelines recommend combination of the nicotine patch with bupropion, although this combination is not recommended in other countries.[2] Combination treatment with nortriptyline and NRT is not supported by the available evidence base.

Primary options

bupropion hydrochloride: 150 mg orally (extended-release) once daily for 3 days initially, followed by 150 mg twice daily for 7-12 weeks

Secondary options

nortriptyline: 25 mg orally once daily at bedtime for 3 days initially, followed by 50 mg once daily at bedtime for 4 days, then 75 mg once daily at bedtime thereafter for at least 12 weeks, adjust dose according to response, maximum 125 mg/day

active smokers ready to quit: pregnant/breastfeeding women or adolescents

Back
1st line – 

brief or comprehensive intervention for smoking cessation

Smoking in pregnancy and smoking in adolescents represent special circumstances with additional considerations.

As in the general adult population, the initial approach to smoking cessation varies according to location of practice. Two commonly used models are:​ i) a brief intervention for smoking cessation, commonly based on an “Ask, Advise, Assist” structure, which encourages clinicians to ask patients about tobacco use, advise them to quit, and assist them by signposting them to specialist smoking cessation services offering pharmacotherapy and behavioral counseling; ii) a more comprehensive intervention for smoking cessation, which can be provided using the "5 A's" structure: 1) ask about tobacco use; 2) advise to quit through clear, personalized messages; 3) assess willingness to quit; 4) assist in quitting; and 5) arrange follow-up and support.[71]

Smoking during pregnancy is a well-established risk factor for adverse pregnancy outcomes including preterm deliveries, low birth weight, and preterm-related deaths, and it is still prevalent to varying degrees globally.[7][156]​​ All pregnant women who smoke should be advised on the adverse effects of smoking on their fetus (low birth weight, preterm birth) and offered access to smoking cessation interventions.[157]​ Likewise, all adolescents who smoke should be advised to quit smoking, and offered evidence-based interventions.[63] Data on efficacy of cessation treatments in adolescents are limited.​[62][161] [ Cochrane Clinical Answers logo ] ​​ This is due, in part, to challenges in conducting studies in this population. In addition, the experience of smoking and smoking cessation may differ between this age group and adults. For instance, levels of nicotine dependence may not be equal to those of adult smokers.

Back
Plus – 

behavioral counseling

Treatment recommended for ALL patients in selected patient group

In pregnancy, behavioral and psychological interventions are considered first-line treatments in some locations, including the US.[71][157]

The American Academy of Pediatrics (AAP) recommends that for adolescents who smoke and who wish to stop using tobacco, clinicians offer referral for a behavioral intervention for smoking cessation.[60]

In the UK, the National Institute for Health and Care Excellence (NICE) recommends behavioral counseling as one of a range of treatment options (both pharmacologic and nonpharmacologic) for smoking cessation in pregnant women and adolescents.[63]

Behavioral counseling interventions to prevent tobacco use in children and adolescents are effective, but the data on efficacy of cessation treatments in adolescents are limited.​[62][161] [ Cochrane Clinical Answers logo ] ​​ One Cochrane review found evidence to suggest that behavioral counseling delivered via a group setting is effective in increasing smoking cessation among adolescents.[161] 

Back
Consider – 

nicotine replacement therapy (NRT)

Treatment recommended for SOME patients in selected patient group

Recommendations on pharmacologic treatment for smoking cessation in pregnancy and in adolescents differ according to country of practice, and clinicians should be familiar with local guidance.

In pregnancy, behavioral and psychological interventions are considered first-line treatments in the US.[71][157]​​​ While not expressly recommending against using medicines, the US Preventive Services Task Force (USPSTF) concluded that the current evidence was insufficient to assess the balance of benefits and harms of pharmacologic interventions, including NRT, for tobacco cessation in pregnant or breastfeeding women.[71] The American College of Obstetricians and Gynecologists (ACOG) recommends using NRT only after a detailed discussion with the patient of the known risks of continued smoking, the possible risks of NRT, and need for close supervision.[159]

In the UK, the National Institute for Health and Care Excellence (NICE) recommends that NRT be considered alongside behavioral counseling in pregnant women who use tobacco, as most smoking-related health problems are caused by other components in tobacco smoke, not by the nicotine.[63]​ Use of NRT instead of smoking reduces their nicotine exposure.[160]

One Cochrane review determined that NRT used for smoking cessation in pregnancy may increase smoking cessation rates in late pregnancy; however, the evidence is of low certainty and there was no conclusive evidence on either positive or negative effects on birth outcomes.[158]​ There is insufficient evidence on either the effectiveness or the safety of bupropion or varenicline for smoking cessation in pregnancy.[158]​ NICE advises against using other pharmacotherapy options for smoking cessation, such as varenicline or bupropion, during pregnancy and breastfeeding.[63]

In adolescents, the USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of primary-care feasible interventions for smoking cessation in children and adolescents younger than 18 years.[62]​ The American Academy of Pediatrics (AAP) recommends that smoking cessation pharmacotherapy (with NRT) may be considered for adolescents who are moderately to severely dependent on tobacco, in conjunction with behavioral counseling.[60]

UK guidance from NICE recommends that clinicians consider NRT for children and adolescents ages 12 years and over who are smoking and dependent on tobacco, in conjunction with behavioral counseling.[63]

In one Cochrane review, there was no clear evidence for the effectiveness of pharmacologic treatment (including NRT) in young people.[161]​ However, a review of studies of pharmacotherapy for smoking cessation in adolescents concluded that if an adolescent shows signs of dependence, a nicotine patch may be prescribed in addition to a behavioral intervention.[162]​ One trial suggested that a combination of NRT and cognitive behavioral therapy is associated with significantly higher abstinence rates in adolescent smokers at 6 months.[163]

Use of other types of pharmacotherapy for smoking cessation (e.g., varenicline, bupropion) is not recommended in those under the age of 18 years.[63]

Consult a specialist for guidance on selection of treatment in pregnant/breastfeeding women and adolescents.

active smokers not ready to quit

Back
1st line – 

brief intervention for smoking cessation

A brief advice intervention for smoking cessation may be given in as little as 30 seconds, and involves: 1) Asking about current and past smoking behavior. 2) Advising on the risks of smoking and the benefits of quitting smoking by providing verbal and written information. 3) Advising on the options for quitting smoking, including behavioral counseling and evidence-based medication for smoking cessation. 4) Dependent on local service arrangements, referring the person to a specialist service (e.g., local smoking cessation service, tobacco dependence specialist, and/or telephone quitline) if they wish to quit smoking.[63]

Explain that a combination of drug treatment and behavioral counseling has been shown to improve smoking cessation rates and may be the best option.[63]

Physicians may be more effective in promoting attempts to quit smoking if they offer assistance to all smokers rather than only those who are motivated to quit smoking.[110]​ If the offer of a brief advice intervention for smoking is declined, it may still be offered at future consultations, as brief advice interventions are designed to be given repeatedly without antagonizing the patient.[63] It is not uncommon for life events and changes in circumstances to precipitate quit attempts even by people who appear to be entrenched smokers.[111]

People should be advised with clear, strong, and personalized messages: for example, 1) smoking cessation is the most important action for future health, 2) tie to current medical problems if applicable, and 3) mention risks of secondhand smoke to family.

"Quitting tobacco use is the most important action you can take to improve your health and increase the quality and length of your life. If you currently smoke, when you quit, your loved ones will have less exposure to secondhand smoke - a known cause of asthma, respiratory infections, heart disease, and lung cancer. In addition, you will save money, improve your sense of taste, and keep your clothes, car, and house smelling fresher."

Back
Plus – 

motivational messages

Treatment recommended for ALL patients in selected patient group

Open-ended questions are asked to encourage the smoker to move toward thinking about quitting.

Relevance: patient is asked how tobacco use relates to their own situation.

Risks: patient is asked about risks of continued tobacco use.

Rewards: patient is asked about benefits of quitting.

Roadblocks: patient is asked to identify barriers to quitting and possible solutions.

Repetition: advice to quit and motivational messages should be repeated every time the patient is seen.

Conversation should end with a statement that many people have successfully quit and that most people who smoke make repeated quit attempts before they are successful. Help is available and they can be connected with resources when they are ready to try.[73]

Back
Consider – 

harm-reduction measures

Treatment recommended for SOME patients in selected patient group

Many smokers are unable or unwilling to quit smoking abruptly even when offered pharmacotherapy. Harm reduction measures may be considered for this group.[63][132]

Approaches to harm reduction vary and include: cutting down before stopping smoking, with or without pharmacotherapy (varenicline or nicotine replacement therapy [NRT]); smoking reduction, with or without pharmacotherapy (varenicline or NRT); or temporary abstinence from smoking, with or without pharmacotherapy (varenicline or NRT).[63]

Shared decision making allows selection of the most suitable approach for the individual.

Reviews of randomized studies of "NRT-assisted reduction to stop" (also known as cut down to quit) demonstrate that the long-term abstinence rates among smokers provided NRT for this purpose are double those among smokers given placebo, and that adverse events are not increased despite receiving nicotine from both NRT and cigarettes.[151][152][153]​​​ Forms of NRT that have been studied include the use of nicotine gum or inhaler for up to 18 months​​​ and the use of nicotine patches for 6 weeks before a quit date.[151][152][153] Many of these studies include behavioral counseling.

For people who are not willing to quit in the next month, but are willing to reduce cigarette consumption and quit in 3 months, varenicline therapy for 24 weeks has been shown to significantly increase smoking cessation rates.[154]

However, neither reduction-to-quit nor abrupt quitting interventions result in superior long-term quit rates when compared with one another.[155]

Note that NRT may be considered in some circumstances in pregnancy, and for adolescents, depending on local guideline recommendations; however, use of other medicines including varenicline is not recommended for pregnant or breastfeeding women, or adolescents.[62][63][71][159]​​​​ Consult a specialist for guidance on selection of treatment in pregnant/breastfeeding women and adolescents.

The choice of nicotine delivery method is guided by patient preferences, prior experience, and availability. In most countries, the patch and gum are available without a prescription. Product literature should be consulted for further guidance on dosage of specific brands of NRT products.

NRT should be started at the same time as the planned quit date. Varenicline is relatively slow-acting, and so should be started 1-2 weeks in advance of the quit date.[63]

Primary options

nicotine transdermal: 21 mg once daily for 6 weeks initially, followed by 14 mg once daily for 2 weeks, followed by 7 mg once daily for 2 weeks

More

OR

nicotine transmucosal: 2-4 mg gum every 1-2 hours for 6 weeks, then taper gradually over 6 weeks, maximum 24 gum pieces/day

Secondary options

varenicline: 0.5 mg orally once daily for 3 days initially, followed by 0.5 mg twice daily for 4 days, followed by 1 mg twice daily for 12-24 weeks

back arrow

Choose a patient group to see our recommendations

Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer

Use of this content is subject to our disclaimer